This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orlova, A. Articles by Feldwisch, J. Search for Related Content PubMed PubMed Citation Articles by Orlova, A. Articles by Feldwisch, J.

Synthetic Affibody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors

¹ Affibody AB, Bromma, Sweden; ² Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University; and ³ Department of Hospital Physics, Uppsala University Hospital, Uppsala, Sweden

Requests for reprints: Joachim Feldwisch, Affibody AB, Voltavägen 13, P.O. Box 20137, SE-16102 Bromma, Sweden. Phone: 46-859883852; Fax: 46-859883801; E-mail: joachim.feldwisch{at}affibody.com.

The Affibody molecule Z_{HER2:342-pep2}, site-specifically and homogeneously conjugated with a 1,4,7,10-tetra-azacylododecane-N,N',N'',N'''-tetraacetic acid (DOTA) chelator, was produced in a single chemical process by peptide synthesis. DOTA-Z_{HER2:342-pep2} folds spontaneously and binds HER2 with 65 pmol/L affinity. Efficient radiolabeling with >95% incorporation of ¹¹¹In was achieved within 30 min at low (room temperature) and high temperatures (up to 90°C). Tumor uptake of ¹¹¹In-DOTA-Z_{HER2:342-pep2} was specific for HER2-positive xenografts. A high tumor uptake of 23% injected activity per gram tissue, a tumor-to-blood ratio of >7.5, and high-contrast gamma camera images were obtained already 1 h after injection. Pretreatment with Herceptin did not interfere with tumor targeting, whereas degradation of HER2 using the heat shock protein 90 inhibitor 17-allylamino-geldanamycin before administration of ¹¹¹In-DOTA-Z_{HER2:342-pep2} obliterated the tumor image. The present results show that radiolabeled synthetic DOTA-Z_{HER2:342-pep2} has the potential to become a clinically useful radiopharmaceutical for in vivo molecular imaging of HER2-expressing carcinomas. [Cancer Res 2007;67(5):2178–86]

This article has been cited by other articles:

				S. B. Lee, M. Hassan, R. Fisher, O. Chertov, V. Chernomordik, G. Kramer-Marek, A. Gandjbakhche, and J. Capala Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging Clin. Cancer Res., June 15, 2008; 14(12): 3840 - 3849. [Abstract] [Full Text] [PDF]

				Z. Cheng, O. P. De Jesus, M. Namavari, A. De, J. Levi, J. M. Webster, R. Zhang, B. Lee, F. A. Syud, and S. S. Gambhir Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules J. Nucl. Med., May 1, 2008; 49(5): 804 - 813. [Abstract] [Full Text] [PDF]

				N. Kronqvist, J. Lofblom, A. Jonsson, H. Wernerus, and S. Stahl A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry Protein Eng. Des. Sel., April 1, 2008; 21(4): 247 - 255. [Abstract] [Full Text] [PDF]

				J. Lofblom, J. Sandberg, H. Wernerus, and S. Stahl Evaluation of Staphylococcal Cell Surface Display and Flow Cytometry for Postselectional Characterization of Affinity Proteins in Combinatorial Protein Engineering Applications Appl. Envir. Microbiol., November 1, 2007; 73(21): 6714 - 6721. [Abstract] [Full Text] [PDF]